Search clinical trials for: atezolizumab

Total 794 results

Glenmark Specialty S.A.

Recruiting

A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.

Lymphoma | Advanced Solid Tumor

United States, India
Baylor College of Medicine
Genentech, Inc.

Not yet recruiting

Neoadjuvant Chemoimmunotherapy for Resectable Non-Metastatic Proficient Mismatch Repair (PMMR) Colon Cancer

Stage I Colon Cancer | Stage II Colon Cancer | Stage III Colon Cancer

United States
Genentech, Inc.
Chugai Pharmaceutical Co.

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Gastric Cancer | Metastatic Solid Tumor | Non-small Cell Lung Cancer | Pancreatic Ductal Adenocarcinoma

Korea, Republic of, Spain, Japan, New Zealand, Australia, United States, Italy, Brazil
Hoffmann-La Roche

Recruiting

A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study (UmbrellaMAX)

Cancer

Korea, Republic of, United Kingdom, Japan, Costa Rica, Thailand, Belgium, Taiwan, Russian Federation, Mexico, Poland, France
Jun Zhang, MD, PhD
Genentech, Inc.; Exelixis

Not yet recruiting

A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) (Cabatezo-1)

Lung Cancer | NSCLC Stage IV | Advanced NSCLC | Metastatic NSCLC - Non-Small Cell Lung Cancer

United States
Biotheus Inc.

Recruiting

A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC

SCLC

China
National Cancer Institute (NCI)

Recruiting

Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

Gastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Gastroesophageal Junction Adenocarcinoma | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric... and other conditions

United States
Pfizer

Recruiting

A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. (DELINOR)

Non-Small Cell Lung Cancer

Norway
Shuhong Yi

Recruiting

Hepatic Arterial Infusion Chemotherapy in Combination With Atezolizumab and Bevacizumab for Second-line Treatment of Patients With Recurrent Liver Cancer After Liver Transplantation

Recurrent Liver Cancer After Liver Transplantation

China
Institut für Klinische Krebsforschung IKF GmbH...
Roche Pharma AG; Thoraxklinik-Heidelberg gGmbH

Recruiting

NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing

Non-small Cell Lung Cancer

Germany
Alliance Foundation Trials, LLC.
Genentech, Inc.

Recruiting

Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC

NSCLC

United States
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer (PICASSO)

Small Cell Lung Cancer

Italy
Intergroupe Francophone de Cancerologie Thoracique

Recruiting

Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy (ADAPTABLE)

Non Small Cell Lung Cancer

France
Yale University
Genentech, Inc.

Recruiting

Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC

Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma

United States
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition (DETERMINE)

Melanoma | Neoplasms by Histologic Type | Lymphoproliferative Disorders | Neoplasms by Site | Cancer | Colorectal Neoplasms | Endometrial Neoplasms | Malignant Neoplasm | Malignancy

United Kingdom
University Hospital, Antwerp
Roche Pharma AG; Algemeen Ziekenhuis Maria Middelares; Kom Op Tegen Kanker; Vitaz

Recruiting

Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma (Immuno-MESODEC)

Malignant Pleural Mesothelioma

Belgium
Seoul National University Hospital

Recruiting

Ate-Bev Early Response Prediction Model in Advanced HCC

Hepatocellular Carcinoma | Atezolizumab-bevacizumab | Response Evaluation

Korea, Republic of
Sonnet BioTherapeutics
Hoffmann-La Roche

Recruiting

Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer

Advanced Solid Tumor | Platinum-resistant Ovarian Cancer

United States, Australia
Sun Yat-sen University

Recruiting

TACE-HAIC Plus Atezolizumab and Bevacizumab for Unresectable HCC: a Phase 2 Clinical Trial

Hepatocellular Carcinoma

China
Medical University of Vienna

Recruiting

FMT in IT-refractory HCC - FAB-HCC Pilot Study

Hepatocellular Carcinoma

Austria
Liza Villaruz, MD
Genentech, Inc.

Recruiting

Carboplatin, Pemetrexed, and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases

Non-small Cell Lung Cancer

United States
National Taiwan University Hospital

Recruiting

Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients

Locally Advanced Esophageal Squamous Cell Carcinoma

Taiwan
Karolinska University Hospital

Recruiting

Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in Metastatic Triple Negative Breast Cancer (MIMIR-mTNBC)

Metastatic Triple-Negative Breast Carcinoma

Sweden
Replimune Inc.
Roche Pharma AG

Not yet recruiting

RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC

Recurrent Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | Locally Advanced Hepatocellular Carcinoma

United States, United Kingdom, France, Germany, Greece
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol (DETERMINE)

Solid Tumor | Haematological Malignancy

United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy

Liver Cancer

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

Advanced Rare Malignant Solid Neoplasm | Rare Malignant Solid Neoplasm | Refractory Rare Malignant Solid Neoplasm

United States
Tongji Hospital
The Second Affiliated Hospital of Fujian Medical University; Geneplus-Beijing... and other collaborators

Recruiting

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma (CCGLC-008)

Hepatocellular Carcinoma Non-resectable

China
Wan-Guang Zhang
The Second Affiliated Hospital of Fujian Medical University; Geneplus-Beijing... and other collaborators

Recruiting

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma (CCGLC-001)

Hepatocellular Carcinoma Non-resectable

China
Gustave Roussy, Cancer Campus, Grand Paris

Recruiting

Clinical Investigation Evaluating Safety and Efficacy of Selective Intra-arterial 166Holmium Radiation Therapy in Combination With Atezolizumab and Bevacizumab for Non Resectable Hepatocellular Carcinoma (HOLMBRAVE)

Hepatocellular Carcinoma

France
Genprex, Inc.

Recruiting

Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients (Acclaim-3)

Small Cell Lung Cancer Extensive Stage

United States
Fondazione IRCCS Istituto Nazionale dei Tumori,...
University of Milan; IFOM, The FIRC Institute of Molecular Oncology

Not yet recruiting

FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction (FASTIMMUNE)

Small Cell Lung Carcinoma

Italy
Michael Dill
University of Cologne; German Cancer Research Center; Heidelberg University; Universitätsmedizin... and other collaborators

Not yet recruiting

Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA) (FLORA)

Immunotherapy

Germany
Nikolaj Frost MD
Roche Pharma AG; Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus...

Recruiting

Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma (ANTELOPE)

Non-Small Cell Lung Cancer Metastatic

Germany
M.D. Anderson Cancer Center
Genentech, Inc.

Recruiting

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

Squamous Cell Carcinoma | Oral Cavity Squamous Cell Carcinoma

United States
Federation Francophone de Cancerologie Digestive

Not yet recruiting

Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy (TRIPLET)

Metastatic Cancer | Metastatic Tumor | HCC - Hepatocellular Carcinoma

France
Grupo Espanol Multidisciplinario del Cancer Digestivo
Hoffmann-La Roche

Recruiting

Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS) (TIRANUS)

Squamous Cell Carcinoma of the Anal Canal

Spain
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors (SKYSCRAPER-11)

PD-L1-selected Solid Tumors

Spain, Korea, Republic of, China, Taiwan, Turkey, Greece, United States, Croatia, Serbia, Canada, Mexico, Cyprus, Georgia
Fudan University
Huazhong University of Science and Technology; LinkDoc Technology (Beijing)...

Not yet recruiting

Effect and Safety of Huaier Granules Combined With Targeted Drugs and Anti-PD-(L)1 Antibody Compared With Targeted Drugs Combined With Anti-PD-(L)1 Antibody in First Line Treatment of Unresectable Hepatocellular Carcinoma(uHCC)

Unresectable Hepatocellular Carcinoma
Hoffmann-La Roche

Recruiting

A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

Urothelial Cancer

Korea, Republic of, United States, Brazil, China, France, Germany, Mexico, Poland, Denmark, Italy, Turkey, Greece, Spain, United Kingdom, Australia
Samsung Medical Center

Recruiting

Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion

Hepatocellular Carcinoma | Portal Vein Thrombosis

Korea, Republic of
Northwestern University
National Cancer Institute (NCI)

Recruiting

Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk

Hepatocellular Carcinoma

United States
RayzeBio, Inc.

Recruiting

Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

SCLC,Extensive Stage

United States, Puerto Rico
Kamya Sankar
University of Michigan; Genentech, Inc.; VA Ann Arbor Healthcare System

Not yet recruiting

Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases (BELIEVE)

Liver Metastases | Extensive-stage Small-cell Lung Cancer

United States
Genentech, Inc.

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Melanoma | Cervical Cancer | HCC | Gastric Cancer | Esophageal Cancer | NSCLC | Urothelial Carcinoma | HNSCC | Locally Advanced or Metastatic Solid Tumors | TNBC | Clear Cell RCC

Korea, Republic of, Netherlands, Spain, United States, Australia, Canada, Belgium
University Hospital, Grenoble
NETRIS Pharma

Recruiting

Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC (Liver-NET1)

Hepatocellular Carcinoma

France
UNC Lineberger Comprehensive Cancer Center
Genentech, Inc.; Oncoceutics, Inc.

Recruiting

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Metastasis | Endometrial Cancer

United States
Ronald Buckanovich
Genentech, Inc.

Recruiting

Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

PARP Inhibitor | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Hedgehog Inhibitor

United States
University of Texas Southwestern Medical Center
Genentech, Inc.

Recruiting

LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC (LOST-B)

Hepatocellular Carcinoma

United States
Centre Hospitalier Universitaire de Besancon
GERCOR - Multidisciplinary Oncology Cooperative Group; PRODIGE

Recruiting

Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma (TERTIO)

Hepatocellular Carcinoma

France

Search clinical trials for: atezolizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Georgia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations